Treatment of autoimmune hemolytic anemias
review
OA: gold
CC0
⤵ 3 in-corpus citations
Abstract
Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder caused by autoantibodies directed against self red blood cells. It can be idiopathic or secondary, and classified as warm, cold (cold hemagglutinin disease (CAD) and paroxysmal cold hemoglobinuria) or mixed, according to the thermal range of the autoantibody. AIHA may develop gradually, or have a fulminant onset with life-threatening anemia. The treatment of AIHA is still not evidence-based. The first-line therapy for warm AIHA are corticosteroids, which are effective in 70-85% of patients and should be slowly tapered over a time period of 6-12 months. For refractory/relapsed cases, the current sequence of second-line therapy is splenectomy (effective approx. in 2 out of 3 cases but with a presumed cure rate of up to 20%), rituximab (effective in approx. 80-90% of cases), and thereafter any of the immunosuppressive drugs (azathioprine, cyclophosphamide, cyclosporin, mycophenolate mofetil). Additional therapies are intravenous immunoglobulins, danazol, plasma-exchange, and alemtuzumab and high-dose cyclophosphamide as last resort option. As the experience with rituximab evolves, it is likely that this drug will be located at an earlier point in therapy of warm AIHA, before more toxic immunosuppressants, and in place of splenectomy in some cases. In CAD, rituximab is now recommended as first-line treatment.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (100)
- Danazol in autoimmune haemolytic anaemia via openalex
- Efficacy of Danazol in Hematologic Disorders via openalex
- Management of Evans syndrome via openalex
- [The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome]. via openalex
- Warm Autoimmune Hemolytic Anemia: Recent Progress in Understanding the Immunobiology and the Treatment via openalex
- doi:10.1016/b978-0-443-08559-8.x5001-8 via openalex
- doi:10.1111/j.1365-2141.2007.06664.x via openalex
- doi:10.3324/haematol.12682 via openalex
- doi:10.1016/j.ejim.2010.12.016 via openalex
- doi:10.1111/j.1365-2257.1988.tb00019.x via openalex
- doi:10.1182/blood-2002-01-0087 via openalex
- doi:10.1182/blood-2010-03-259325 via openalex
- doi:10.1007/s11899-009-0007-4 via openalex
- doi:10.1007/s00277-010-1123-x via openalex
- doi:10.1182/blood-2009-01-196329 via openalex
- doi:10.1016/s0248-8663(02)00688-4 via openalex
- doi:10.1001/jama.244.15.1688 via openalex
- doi:10.1097/mbc.0b013e3282f9ae12 via openalex
- doi:10.1016/j.dld.2006.12.017 via openalex
- doi:10.1182/blood-2003-10-3597 via openalex
- doi:10.1016/b978-008055232-3.60624-5 via openalex
- doi:10.1001/jama.253.12.1746 via openalex
- doi:10.1002/(sici)1096-8652(199906)61:2<98::aid-ajh4>3.3.co;2-7 via openalex
- doi:10.1080/08880010701360783 via openalex
- doi:10.1111/bjh.12486 via openalex
- doi:10.1016/0002-9343(88)90106-4 via openalex
- doi:10.1159/000222800 via openalex
- W128812423 via openalex
- doi:10.1016/j.clml.2013.02.022 via openalex
- doi:10.1002/pbc.21264 via openalex
- doi:10.1111/j.1600-0609.2005.00437.x via openalex
- W1842247258 via openalex
- W1859967272 via openalex
- doi:10.1056/nejm197706302962602 via openalex
- doi:10.1007/s00277-010-0997-y via openalex
- doi:10.1111/j.0041-1132.2005.04497.x via openalex
- doi:10.1161/circulationaha.110.015008 via openalex
- doi:10.1080/08916930802198436 via openalex
- doi:10.1182/blood.v35.1.68.68 via openalex
- doi:10.1007/s00277-002-0539-3 via openalex
- doi:10.3324/haematol.11709 via openalex
- doi:10.1007/s00464-005-0527-5 via openalex
- doi:10.1111/j.0902-4441.2006.t01-1-ejh2549.x via openalex
- doi:10.1007/s00508-008-0945-1 via openalex
- doi:10.1001/jama.1985.03360090065017 via openalex
- doi:10.1007/s12098-008-0071-0 via openalex
- doi:10.1046/j.1198-743x.2001.00355.x via openalex
- doi:10.1182/blood.v69.3.820.820 via openalex
- doi:10.1182/blood-2010-06-288647 via openalex
- doi:10.1038/sj.leu.2404512 via openalex
- doi:10.1080/10428190500286481 via openalex
- doi:10.1182/blood-2013-02-474437 via openalex
- doi:10.1111/j.1365-2796.2009.02126.x via openalex
- doi:10.1159/000206992 via openalex
- doi:10.1016/j.blre.2012.01.002 via openalex
- doi:10.1038/sj.leu.2404703 via openalex
- doi:10.3324/haematol.2010.036053 via openalex
- doi:10.1182/blood-2009-09-242917 via openalex
- doi:10.1001/jama.1985.03350360072021 via openalex
- doi:10.1007/s00005-013-0232-3 via openalex
- doi:10.1111/j.1537-2995.2008.01957.x via openalex
- doi:10.1002/jca.20096 via openalex
- doi:10.1136/bmj.331.7514.417 via openalex
- doi:10.1038/bmt.2011.185 via openalex
- doi:10.1111/j.1365-2141.2011.08643.x via openalex
- doi:10.1182/blood-2009-04-215368 via openalex
- doi:10.1002/ajh.2830440404 via openalex
- doi:10.4103/0972-9747.58804 via openalex
- doi:10.3324/haematol.11540 via openalex
- doi:10.1002/ajh.20665 via openalex
- doi:10.1053/j.seminhematol.2005.04.003 via openalex
- doi:10.1111/petr.12172 via openalex
- doi:10.1182/blood-2012-11-467209 via openalex
- doi:10.1016/j.tmrv.2007.01.001 via openalex
- doi:10.1080/08880010490514778 via openalex
- doi:10.1111/j.1537-2995.2006.00792.x via openalex
- doi:10.1046/j.1365-2141.2001.03039.x via openalex
- doi:10.1182/blood-2002-11-3547 via openalex
- doi:10.1007/bf01633870 via openalex
- doi:10.1002/ajh.23356 via openalex
- doi:10.1046/j.1365-2141.1996.4871026.x via openalex
- doi:10.1016/j.trsl.2013.09.007 via openalex
- doi:10.1080/1042819031000119235 via openalex
- doi:10.1046/j.1365-2141.1997.3203137.x via openalex
- doi:10.1182/blood-2010-06-291831 via openalex
- doi:10.1002/(sici)1096-8652(199906)61:2<98::aid-ajh4>3.0.co;2-g via openalex
- W2259054830 via openalex
- W2411329165 via openalex
- W6641511288 via openalex
- W6649454092 via openalex
- W6650311467 via openalex
- W6663929486 via openalex
- W6666627447 via openalex
- W6753251306 via openalex
- W6892194231 via openalex
- W7074067584 via openalex
- doi:10.1191/0961203303lu419cr via openalex
- doi:10.7534/j.issn.1009-2137.2013.05.038 via openalex
- doi:10.1002/jca.2920080404 via openalex
- doi:10.1034/j.1600-0609.2000.9l201.x via openalex
Cited by (3)
Source provenance
- openalex
- last seen: 2026-05-11T06:25:09.493344+00:00
License: CC0
· commercial use OK